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1. INTRODUCTION 
Over the centuries, the pharmacological effects of 
preparations from the plant Cannabis sativa have been 
utilized for recreational and medicinal purposes. Due to its 
psychoactive effects and despite its traditional medicinal 
use, cannabis did not gain a wide and lasting acceptance as 
a valuable drug. Different active substances isolated from 
Cannabis sativa were identified and characterized in the 
mid-last-century (1). Modern research studies on cannabis 
started with the structural characterization of 
tetrahydrocannabinol (Δ9-THC, figure 1) by Mechoulam in 
1964 (2). More than 100 phytocannabinoids have been 
isolated from the plant. They all have in common typical 
C21 terpenophenolic skeleton o derivative chemical 
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RESUMEN: El sistema endocannabinoide (SEC) ha 
sido reconocido por su gran relevancia a nivel 
neuromodulador. Este sistema juega un importante rol 
en la regulación de numerosos procesos fisiopatológicos 
tales como el cáncer, el dolor o la neurodegeneración. A 
pesar del amplio potencial terapéutico de los ligandos 
cannabinoides, su actual uso clínico se limita al 
tratamiento del dolor, la emesis y la mejora del apetito. 
El problema fundamental asociado al tratamiento con 
cannabinoides radica en la imposibilidad actual de 
separar los efectos terapéuticos de la acción psicoactiva. 
Por tanto, es de gran interés la identificación de nuevos 
cannabinoides sintéticos con efectos secundarios 
reducidos. Otros receptores acoplados a proteínas G, 
como GPR55, también se han propuesto como posibles 
miembros del sistema endocannabinoide. Sin embargo, 
esta categorización aún no ha sido confirmada debido a 
la falta de herramientas farmacológicas que permitan 
caracterizar apropiadamente las funciones biológicas de 
GPR55 y su relación con el SEC. En este contexto, se 
identificó el esqueleto de cromenopirazol como 
estructura privilegiada para el desarrollo de moléculas 
capaces de modular el sistema endocannabinoide. En 
esta revisión, se van a analizar la farmacología y las 
oportunidades terapéuticas ofrecidas por los diversos 
derivados de cromenopirazol descritos hasta la fecha. 
Posibles perspectivas y aplicaciones futuras así como 
nuevas aproximaciones serán también consideradas. 
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structures that can be classified in 11 families: Δ9-THC, 
Δ8-THC, cannabigerol (CBG), cannabichromene (CBC), 
cannabidiol (CBD), cannabinodiol (CBND), cannabielsoin 
(CBE), cannabicyclol (CBL), cannabinol (CBN), and 
cannabitriol (CBT), miscellaneous-type cannabinoids. 
Whereas Δ9-THC is the most abundant and main 
psychoactive constituent of cannabis, CBD, the second 
most abundant, is a non-psychotropic substance (3). 
However, Δ9-THC has attracted much attention since its 
discovery. Thus, a considerable amount of 
pharmacological studies was done on its activity 
supporting its value as therapeutic agent and that, before 
the discovery of the endocannabinoid system (ECS). 
Over the past three decades, the ECS has emerged as a 
promising therapeutic target. Two G-protein coupled 
receptors (GPCRs), the cannabinoid receptors type 1 
(CB1R) and type 2 (CB2R), and their endogenous lipid 
ligands were identified in the 1990s as the main 
constituents of the ECS. CB1R is highly expressed in the 
central nervous system (CNS) modulating numerous 
physiological processes such as cognition, emotion or pain 
control. This receptor is also localized in the peripheral 
tissue (liver, kidney, or lung among others) where it 
modulates energy balance and metabolism (4). On the 
other hand, CB2R is mainly expressed in the immune 
system, the gastrointestinal tract and in certain neuronal 
subpopulations. Interestingly, the expression of CB2R in 
the CNS is upregulated upon neuroinflammatory stimuli, 
what confers to this receptor an important role in the 
treatment of neurodegenerative disorders (5). 
The orphan receptors GPR18 and GPR55 have also 
been proposed as potential members of the ECS (6). 
Unfortunately, the current lack of pharmacological tools to 
study these receptors is delaying the understanding of their 
relation with the cannabinoids.  
It is widely demonstrated that compounds targeting the 
ECS have therapeutic potential for the clinical 
management of an ever growing number of disorders (7). 
These include inflammatory and neuropathic pain, 
neurological pathologies, metabolic syndrome, or cancer 
among others (8–10). The only cannabinoids on clinical 
use today are the phytocannabinoids Δ9-THC and CBD, 
and the Δ9-THC synthetic derivative nabilone, which are 
approved for pain, emesis and appetite disorders. Taking 
into account the fact that these compounds lack of 
CB1R/CB2R selectivity, identifying new synthetic selective 
cannabinoids is of great interest. These novel entities 
should be exempt of the undesirable psychotropic effects 
related to the activation of brain CB1R to have greater 
opportunity to be explored as cannabinoid-based 
medicines.  
Numerous cannabinergic ligands have been described 
thus far. Besides the phytocannabinoids previously 
detailed, other modulators of the cannabinoid receptors   
proceeding from endogenous or synthetic sources have 
been identified. These compounds present very different 
chemical structures and pharmacological profiles.  
Endogenous cannabinoids, endocannabinoids, 
comprise a family of polyunsaturated fatty acids that 
structurally differ from phytocannabinoids. These 
molecules, are lipid neurotransmitters that mediate 
retrograde signal from postsynaptic neurons to presynaptic 
ones targeting CBRs (11). Among the most abundant 
endocannabinoids identified so far are anandamide [N-
arachidonoylethanolamine (AEA), figure 1], and 2-
arachidonoylglycerol (2-AG, figure 1).  
In addition, the interest gained by the ECS as valuable 
target for drug discovery led to the synthesis of numerous 
cannabinoid ligands in the last years. The development of 
synthetic endocannabinoid and phytocannabinoid 
analogues, as well as chemically diverse scaffolds, offered 
novel pharmacological opportunities in this field. Among 
the most remarkable synthetic cannabimimetics discovered 
are the well-known aminoalkyindole R-(+)-WIN55,212-2 
(figure 1), and the synthetic phytocannabinoid CP55,940 
(figure 1). Both of them are very potent CB1R/CB2R 
agonists that have been extensively used to investigate the 
endocannabinoid system. Another compound that has 
significantly contributed to the understanding of the 
cannabinoid receptors is the arylpyrazole SR141716A 
(Rimonabant, figure 1) (12). This compound is a potent 
CB1R antagonist/inverse agonist which therapeutic 
potential was confirmed for the management of obesity 
(13), however, it also triggers undesired side effects.  
Other classes of ligands that exhibit interesting 
cannabinoid activity have also been developed by 
pharmaceutical companies and academic research groups. 
For instance, indole-2-carboxamides, such as the CB1R 
allosteric modulator ORG27569 (14), or CB2R ligands 
derived from the 1,8-naphthyridine-3-carboxamide 
scaffold (15,16), were developped. 
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Figure 1. Structure of selected cannabinoid ligands: phytocannabinoids (Δ9-THC, CBN, and CBD); endocannabinoids 
(AEA and 2-AG); synthetic derivatives (CP55,940, WIN55,212-2 and SR141716A).  
The chromenopyrazole appears in the field of 
cannabinoid analogues in 1985, before the discovery of the 
cannabinoid receptors (17). The authors described them as 
heterocyclic-fused benzopyrans, reported their synthesis, 
and concluded that these compounds had no interesting 
levels of activity in the CNS.  In 2012, the 
chromenopyrazole scaffold was re-explored as a 
cannabinoid chemotype taking advantage of the progress 
realized in the understanding of the ECS (figure 2). This 
tricyclic structure was designed in analogy to the classical 
cannabinoid cannabinol (CBN), bearing a benzopyran 
moiety but exploring for the first time the contribution of a 
pyrazole ring in place of the CBN´s phenyl group.  
 
Figure 2. General structural features of the 
chromenopyrazole scaffold. 
Since then, different strategies to target the ECS under 
diverse pathological conditions have driven the exploration 
of structural modifications of this tricyclic core. Structure-
activity relationships as well as the rational understanding 
of ligand-receptor interactions helped fine-tuning the 
potential of the chromenopyrazole scaffold targeting 
diverse pathological conditions. This work, critically 
reviews the findings obtained so far offering future 
perspectives for the use of this versatile scaffold to 
continue unraveling the complex pharmacology of the 
ECS.   
2. CB1R SELECTIVE LIGANDS: APPLICATION IN 
PAIN 
As previously mentioned, the psychotropic side-effects 
of cannabinoid receptor agonists have limited their 
exploitation as medications. These unwanted properties are 
mediated by the CB1Rs located in the CNS, therefore, a 
strategy to selectively target CB1Rs located outside the 
brain is the development of peripherally restricted ligands. 
In an effort to identify novel cannabinoids, the 
chromenopyrazole scaffold was discovered by introducing 
a pyrazole ring to the benzopyran core of classical 
phytocannabinoids (18). The synthesis of these reported 
molecules is summarized in scheme 1. 
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Scheme 1. Synthesis of chromenopyrazoles. Reaction conditions: (i) BBr3, CH2Cl2, overnight, 0 ºC-r.t.; (ii) 3,3-
dimethylacrylic acid, methanesulfonic acid, P2O5, 8 h, 70 ºC, (iii) a) NaH, THF, MW, 25 min, 45 ºC; b) ethyl formate, MW, 
25 min, 45 ºC; (iv) corresponding hydrazine, EtOH, 1-4 h, 40 ºC. R1: pentyl or 1,1-dimethylheltyl; R2: hydrogen, methyl, 
ethyl, or dichlorophenyl (18). 
Briefly, these compounds were prepared from the 
resorcinol (2) previously obtained after demethylation of 
the corresponding 1,3-dimethoxybenzene (1) with boron 
tribromide. Chromanone 3 was obtained by treatment of 
the resorcinol with 3,3-dimethylacrylic acid in presence of 
phosphorous pentoxide (19). Subsequent α–formylation of 
the chromanones under microwave conditions using 
sodium hydride followed by the addition of ethyl formate 
yielded 4. Finally, condensation of the β-ketoaldehyde (4) 
with the appropriate hydrazine gave the N1- and N2-
substituted chromenopyrazoles regioisomers (5 and 6) with 
different relative ratios. 
The synthesized compounds were evaluated in vitro for 
their ability to displace the radioligand [3H]CP55,940 from 
human CB1R and CB2R (18). These affinity binding assays 
revealed that among the lipophilic alkyl chains tested at 
R1, aliphatic pharmacophoric position in 
phytocannabinoids, the 1,1-dimethylheptyl group is clearly 
preferred. Pentyl alkyl side chains lead to weaker binders 
or compounds that do not have affinity at all for these 
receptors. However, the 1,1-dimethylheptyl analogues 
display significant to high affinity and selectivity for CB1R 
(CB1R Ki: 4.5–28.5 nM; CB2R Ki: >40000 nM). In what 
concerns the substitution on the pyrazole ring or the nature 
of the R2 substituents, the affinity values remained similar 
among 1,1-dimethylheptyl analogues (18). Figure 3 
summarizes the structural features of this series of 




Figure 3. Summary of chromenopyrazole structural features related to CBR affinity.  
Mouse vas deferens functional assays were performed 
with the compounds that exhibit higher binding affinities 
(7, 8a, and 8b, figure 4). These chromenopyrazoles 
inhibited the electrically evoked contractile response of 
this tissue confirming their agonistic properties (18). The 
most potent and effective agonist (8a) was then tested in 
the cannabinoid mouse tetrad. This in vivo behavioral test 
indicates if a compound has CNS-mediated effects. 
Compound 8a did not induce modifications in any of the 
tetrad parameters at doses up to 10 mg/kg which indicates 
that it is not acting in the brain, and thus, not readily 
crossing the blood–brain barrier. 
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Figure 4. Structure and affinity of the three more potent and selective CB1R ligands of the first chromenopyrazole series 
(18). 
In a further approach to evaluate the therapeutic 
potential of the peripheral CB1R agonist 8a, this 
chromenopyrazole was tested in a rat model of orofacial 
pain. Interestingly, compound 8a showed a remarkable 
antinociceptive response probably mediated by peripheral 
mechanisms. 
To sum up, in this study, the chromenopyrazole 
scaffold was reported for the first time opening new 
avenues in the cannabinoid chemistry scenario. Among 
this first series of chromenopyrazoles, non-psychoactive 
and selective CB1R agonists with peripheral 
antinociceptive properties were identified (18).  
3. TOWARDS CB2R SELECTIVITY: APPLICATION 
IN NEURODEGENERATIVE DISEASES 
A second approach to pursue the separation of the 
therapeutic effects of cannabinoids from their psychotropic 
effects is the search of CB2R selective ligands. Although 
CB1R is the main receptor of the CNS, the presence of 
CB2R in microglia and neuronal cells as well as its role in 
the immune system (20–22), suggest the possibility to use 
CB2R agonists to treat certain neurological conditions 
without psychotropic unwanted effects (23,24). The role of 
the CB2R in the CNS is closely related to neuronal 
damage, particularly inflammatory. Therefore, as 
suggested by numerous studies, CB2R represents a 
promising target for alleviating the neuronal deterioration 
and neuroinflammation triggered by neurodegenerative 
diseases (5,23). 
In an attempt to target the CB2R, different structural 
modifications on the chromenopyrazole scaffold were 
accomplished while retaining the 1,1-dimethylheptyl 
aliphatic chain that provided better results in the previous 
study. In this case, the conversion of the phenolic 
hydroxyl, a pharmacophoric moiety of classical 
cannabinoids, to different alkoxy groups was explored. 
Moreover, different pyrazole substituents as well as 
bioisosteric replacement of the pyrazole by an isoxazole 
were also intended for further fine-tuning of CBRs affinity 
and selectivity (25). 
The synthesis of these chromenopyrazoles has been 
reported to be achieved by alkylation of the phenolic 
oxygen of the chromenopyrazoles described in the 
previous section with the corresponding alkyl halides. The 
bioisosteric replacement by an isoxazole moiety, was 
obtained upon condensation of the β-ketoaldehyde (4) with 
hydroxylamine hydrochloride (25). 
Figure 5 provides an overview of the affinity trends 
that can be featured from the radioligand binding assays of 
these chromenopyrazoles at the cannabinoid receptors 
CB1R and CB2R (25). As detailed in the previous section, 
chromenopyrazoles bearing a free phenolic hydroxyl group 
display CB1R affinity and selectivity. Phenolic alkylation 
of these compounds causes a drastic loss of CB1R affinity, 
whereas high CB2R selectivity was achieved with 
alkoxychromenopyrazoles derivatives. These results 
suggest that the phenolic hydroxyl may play a crucial role 
in CBR selectivity.  
Another relevant conclusion extracted from reported 
structure-activity relationship (SAR) is that the nature of 
the pyrazole substituent influences the affinity for the 
cannabinoid receptors. In general, alkyl groups showed 
better affinity for CB2R compared to aryl substituents. 
Bioisosteric replacement of the pyrazole by an isoxazole 
results in cannabinoid ligands with affinity in the 
nanomolar range. Upon phenolic alkylation, 
chromenoisoxazoles follow the same affinity pattern 
observed for the chromenopyrazoles. 
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Figure 5. Summary of alkoxychromenopyrazole and chromenoisoxazoles structural features related to CBR affinity.  
Among these novel compounds, CB2R selective 
ligands with the best affinity values (Ki < 100 nM) were 
selected for functional appraisal. Most of these ligands 
showed CB2R full agonism in forskolin-stimulated cAMP 
accumulation experiments and GTPγS binding assays 
exhibiting potency values in the nanomolar range. The 
most potent and efficacious ligand of this series is the 
chromenoisoxazole 9 (figure 6), which displays higher 
CB2R selectivity and potency than well-known 
cannabinoid agonists such as HU308 or JWH133 (25).  
 
 
Figure 6. Cannabinoid receptor affinity and functional data of the most potent and efficacious CB2R ligand of this series 
(chromenoisoxazole 9). 
Selected compounds of this series were investigated 
from a molecular modeling perspective in order to 
understand the governing ligand-receptor interactions that 
trigger CBR affinity and selectivity. Docking studies 
revealed that the presence of the pyrazole or isoxazole 
moiety as well as the phenolic oxygen play a crucial role 
in the binding mode of these compounds to the active state 
models of CB1R and CB2R. For CB1R affinity, the 
phenolic lone pair need to be accessible to hydrogen bond 
with K3.28(192), as in phenols 7, 8a or 8b. O-alkylation of 
the initial phenolic hydroxyl of the scaffold leads to 
selective CB2R ligands (figure 5). This might be due to the 
different orientation and low accessibility of the lone pair 
of electrons of the phenolic oxygen, essential for CB1R 
activation. The steric hindrance generated by the O-
substituent in the CB1R binding site impacts their affinity 
towards this receptor; however, it clearly enables CB2R 
activity. Substituted phenols align in the proper orientation 
in the CB2R binding site leading to an interaction of 
S6.58(268) with the ligand pyran oxygen (25). These 
structural studies might lead to further fine-tuning of this 
versatile scaffold.  
In order to evaluate the therapeutic potential of the 
promising CB2R selective agonist, chromenoisoxazole 9, 
additional in vitro and in vivo assays were performed. To 
evaluate its neuroprotective profile, 9 was tested in an in 
vitro model of neuronal death determining the cell viability 
of a neuronal cell line (M213-2O) upon 
neuroinflammatory stimuli (26). Interestingly, compound 9 
showed a dose-dependent neuroprotective effect, and 
therefore, its potential was evaluated in an in vivo model 
based on mitochondrial damage and inflammation. This 
model, which is reminiscent of Huntington’s disease (HD), 
is generated by intrastriatal application of malonate 
toxicity in rats. The administration of this 
chromenoisoxazole clearly decreased the volume of the 
striatal lesion as confirmed by histopathological studies 
(26). Moreover, it was demonstrated that these 
neuroprotective effects were mediated by the ability of 9 to 
activate CB2R (effect reversed by administration of CB2R 
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antagonists).  
Additionally, chromenoisoxazole 9 was tested in a 
murine model of multiple sclerosis (MS) induced by 
TMEV. The Theiler’s murine encephalomyelitis virus 
(TMEV) triggers a late-onset demyelinating disease which 
presents similar neuroinflammatory processes to human 
MS. During the acute inflammatory phase, compound 9 
was intraperitoneally administered at a dose of 5 mg/kg 
during 7 days. Treatment with 9 led to a remarkable 
reduction of inflammatory events in TMEV-infected mice 
(25). All these studies demonstrate that chromenoisoxazole 
9 has an outstanding neuroprotective profile due to its 
capacity to selectively activate CB2R. 
In summary, novel fully selective CB2R agonists were 
identified through optimization of the chromenopyrazole 
scaffold. The lead compound of this series, 
chromenoisoxazole 9, has shown antiinflammatory and 
neuroprotective properties in vitro and in vivo in various 
neurological disorders (murine and rat models of MS and 
HD) (25,26).  This molecule presents a promising potential 
for further drug development, in particular, for the 
treatment of neurodegenerative pathologies.   
4. A DUAL APPROACH: TARGETING CANCER 
WITH CANNABINOID-QUINONES 
The development of new effective and safe antitumor 
treatments that improve the aggressive current 
chemotherapies remains an unmet clinical need. Cancer is 
one of the most prevalent diseases and its incidence is 
dramatically increasing (27). Within this pathological 
panorama, the endocannabinoid system emerges as a 
promising anticancer target involved in the modulation of 
the main hallmarks of this disease. 
Δ9-THC and its synthetic derivatives have long been 
known for their palliative effects in cancer patients. In the 
middle 1980´s, dronabinol (Marinol®) and nabilone 
(Cesamet®) were approved for the management of 
chemotherapy-induced nausea and emesis (28). Their 
orexigenic properties and their ability to alleviate pain 
associated with cancer have also been widely evidenced 
(29–34). However, nowadays, they are only prescribed in 
some countries after conventional anti-emetics fail (35,36). 
Besides the aforementioned palliative potential of 
cannabinoids, more recent research revealed that these 
molecules exhibit antitumor effects in numerous in vitro 
and in vivo experimental models of cancer (37–39). The 
activation of cannabinoid receptors on cancer cells 
modulates signaling pathways implicated in cell 
proliferation and survival. Even though the underlying 
mechanisms are not fully unraveled, there is significant 
evidence for the involvement of at least four mechanisms: 
direct inhibition of transformed-cell growth through the 
suppression of mitogenic signal, induction of apoptosis, 
inhibition of tumor angiogenesis and metastasis (40). 
The biological role of the ECS in cancer 
physiopathology is quite complex and far from being 
completely understood.  In fact, this endogenous system is 
upregulated in neoplasms compared with non-tumor tissue 
(38,40–42). However, these observations are tumor type-
specific and therefore, further research is needed to 
understand the regulation of cannabinoid receptor 
expression in each type of cancer (37,41).  
With regard to the clinical translation of the antitumor 
properties of cannabinoids, a pilot clinical trial has been 
reported so far (43), whereas a few more are presently in 
progress. In this phase I pilot trial, the effects of 
intratumoral administration of Δ9-THC were studied in 
nine patients with glioblastoma multiforme, who had failed 
surgical therapy and radiotherapy and exhibited clear 
evidence of tumor progression. The results obtained in this 
study suggested that cannabinoid treatment reduced tumor 
growth rate (43). Nonetheless, more extensive clinical 
studies are needed to extract significant conclusions that 
reinforce the potential utility of cannabinoids as anticancer 
therapeutics.  
Among other pharmacological approaches for cancer 
treatment, cytotoxic quinones represent an important group 
of antineoplastic drugs. Antitumor properties of quinones 
have been widely reported and are still the focus of much 
research (44,45). The cytotoxic activity of quinoid 
derivatives can be accounted for their fast redox cycling 
potential and Michael acceptor properties (46–48). Even 
though their mechanism of action is not completely 
understood, several mechanisms have been suggested. 
Most investigations propose different combinations of 
DNA intercalation (49), topoisomerase inhibition (50), 
DNA alkylation (51,52), and induction of reactive oxygen 
species (ROS) (53) depending on the compound structural 
features.  
Many of the drugs clinically approved or still in 
clinical trials against cancer are quinone-related 
compounds (figure 7). The quinoid moiety is present in 
anthracyclines which are among the most used anticancer 
drugs ever developed (44). Daunorubicin (Cerubidine®) 
and doxorubicin (Adriamycin®), the most prominent 
members of this class of antitumor agents, are clinically 
used in the therapy of solid cancers as well as 
hematological malignancies (54). Likewise, mitoxantrone 
(Novantrone®), a dihydroxyanthracenedione, is approved 
for the treatment of certain types of neoplasms such as 
metastatic breast cancer, acute myeloid leukemia, and non-
Hodgkin's lymphoma (55). Bioreductive alkylating agents 
such as mitomycin C and its derivatives also display 
remarkable antitumor effects. Mitomycin C, a potent DNA 
crosslinker, is a FDA approved drug for the treatment of 
solid tumors (56,57). Additionally, β-lapachone, an ortho-
naphthoquinone, originally isolated from a tree, is also 
being evaluated for its cancer growth inhibitory properties 
in diverse tumors (44). Even though in many cases the 
antitumor mechanisms remain uncertain, it is 
unquestionable that the presence of the quinone moiety is 
exceptionally remarkable in the development of new 
anticancer drugs.  
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Figure 7. Some examples of quinoid compounds with antitumor activity. 
Since cancer is a complex multifactorial disease, 
successful treatment of neoplasms often requires 
pharmaceutical intervention at multiple pathways. This is 
generally accomplished by using a combination of 
different drugs.  However, a very attractive and promising 
approach is to target different anticancer modes of action 
in a single molecule (58–60). In this context, ortho and 
para cannabinoid-quinones were recently reported in the 
literature (61–64). They were designed using the 
chromenopyrazole scaffold as structural core 
(chromenopyrazolediones, figure 8). 
 
 
Figure 8. General structure of ortho and para-chromenopyrazolediones and their related CBR affinity. 
The synthesis of these novel quinone derivatives was 
achieved by regio-controlled oxidation of the phenolic 
chromenopyrazoles (5 and 6, scheme 1) to the 
corresponding 1,2- or 1,4-quinones using with hypervalent 
iodine reagents (63–65). The redox potential of selected 
chromenopyrazolediones was confirmed by cyclic 
voltammetry and electron spin resonance (63). In addition, 
as reported for previous chromenopyrazole derivatives 
(sections 2 and 3), their binding affinity to human CB1R 
and CB2R was tested. As summarized in figure 8, para-
chromenopyrazolediones display affinity for both 
receptors, CB1R and CB2R, in the low micromolar range. 
Interestingly, the unsubstituted pyrazole derivative 
(compound 11, figure 10) stands out showing better 
affinity values at both receptors. On the other hand, ortho-
chromenopyrazolediones are fully selective towards CB2R 
with affinity in the submicromolar range  (63,64). Their 
lack of affinity for the CB1R (higher than 40 µM) 
eliminates any psychotropic side effect that could be 
derived from activation of central CB1R.   
It is noteworthy that chromenopyrazolediones were the 
first cannabinoid structure-related quinones able to bind to 
the cannabinoid receptors. The only quinones related to 
cannabinoid structures (quinones of CBD, THC, and CBN) 
reported previous to the chromenopyrazole derivatives, did 
not display affinity for the cannabinoid receptors (66).  
The biological activity of these phytocannabinoid 
quinones, was attributed to their quinoid structure (67,68) 
independently of their cannabinoid character, since they do 
not bind to CB1R or CB2R.  
The antitumor potential and the mechanism of action of 
the reported chromenopyrazolediones derivatives were 
evaluated in vitro and in vivo in different cancer models. In 
particular, their antiproliferative activity was explored in 
two highly prevalent cancers: Triple Negative Breast 
Cancer (TNBC) and Prostate Cancer (PC). In both cases, 
the endocannabinoid system has been proved to be 
upregulated under these neoplastic conditions, and 
therefore, it represents an appropriate target.  
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 4.1 Chromenopyrazolediones for Triple Negative Breast 
Cancer (TNBC) 
According to the World Health Organization, breast 
cancer is among the most common malignant diseases and 
the second leading cause of cancer death among Western 
women (69). Despite recent advances in earlier detection 
and adjuvant systemic therapies, mortality rates remain 
very high due to the emergence of refractory tumors 
associated with multidrug resistance.  
From an immunopathological perspective, there are 
three main breast cancer subtypes: hormone receptor-
positive, HER2-positive (human epidermal growth factor 
receptor 2) and triple-negative tumors. Triple-negative 
breast cancers (TNBC) are defined by the absence of 
immunohistochemical expression of estrogen, 
progesterone, and HER2 receptors. Although this 
molecular subtype of breast cancer accounts for a low 
percentage of all breast tumors, it represents a vast number 
of deaths (70). TNBC show aggressive clinical behavior, 
this fact, along with the lack of available targeted 
therapies, leave these patients with a bad prognosis (70–
73). Chemotherapy with its well-known side effects is 
currently used as systemic treatment for this cancer (74). 
For that reason, the discovery of new targets and drugs for 
the treatment of this disease is an urgent and essential 
clinical challenge.  
Recent evidence suggests that cannabinoid receptors 
are overexpressed in human breast cancer biopsies 
(42,75,76). Further insights into the endocannabinoid 
upregulation have demonstrated a correlation between 
CB2R expression and tumor aggressiveness in triple-
negative breast cancer cells (42). The putative novel 
cannabinoid receptor GPR55 is also highly expressed in 
these carcinomas (77). Consequently, the ECS represents a 
promising target for the treatment of TNBC (78,79).  
In this context, the antiproliferative potential of the 
recently reported cannabinoid-quinones derived from the 
chromenopyrazole scaffold was explored in models of this 
highly aggressive breast cancer. 
Cell viability, using a human derived triple-negative 
breast cancer cell line, MDA-MB-231, was evaluated after 
treatment with increasing doses of the novel para and 
ortho-chromenopyrazolediones. All the tested 
cannabinoid-quinones displayed growth inhibitory effects 
on triple-negative MDA-MB-231 breast cancer cells, 
displaying low micromolar IC50 values. The para and 
ortho-chromenopyrazolediones bearing an ethyl R 
substituent in the pyrazole (figure 8) are the most potent 
inhibitors of cell proliferation with IC50 values of 2.5 and 
2.8 µM respectively. Because of its antiproliferative 
capacity and its CB2R selective profile, compound 10 
(figure 9) was selected for additional mechanistic and in 
vivo investigations (64).  
 
 
Figure 9. Cannabinoid receptor affinity and half-maximum inhibitory concentrations (IC50) in MDA-MB-231 of ortho-
chromenopyrazoledione 10.  
Compound 10 was further tested in normal Human 
Mammary Epithelial Cells (HMEC). Interestingly, at doses 
up to 30 µM, this cannabinoid-quinone did not exhibit 
cytotoxicity in HMEC. This selective toxicity towards 
cancer cells versus non-transformed mammary cells is 
essential for the development of safer chemotherapies for 
TNBC.   
Deeper studies into the antitumor mechanism of action 
of this compound were accomplished in MDA-MB-231 
cells (64). According to these experiments, CB2R 
activation and the generation of reactive oxygen species 
(ROS) are tightly involved in the antiproliferative action of 
compound 10. Conversely, as expected, neither CB1R nor 
GPR55 mechanisms seem to be involved in the cytotoxic 
effects of chromenopyrazoledione 10 (64).  
Further evaluation of the cellular mechanism 
underlying the antiproliferative effect of compound 10 led 
to examine the involvement of caspase-3 in MDA-MB-231 
cells. Western immunoblotting studies showed the 
procaspase-3 cleavage into caspase-3 confirming the 
proapoptotic effect of cannabinoid quinone 10 on this 
triple-negative breast cancer cell line (62,64).  
Chromenopyrazoledione 10 was then evaluated in a 
murine model of TNBC. Tumor xenografts were generated 
in nude mice by subcutaneous inoculation of MDA-MB-
231 human breast adenocarcinoma cells. After four weeks 
of intraperitoneal treatment with 2 mg/kg, compound 10 
showed to effectively reduce the growth of triple-negative 
xenografts in this animal model. Histopathological 
analysis of treated mice revealed that compound 10 did not 
generate signs of toxicity in organs such as liver, spleen, 
lung, heart, or colon. Volume and weight of final tumors 
was significantly lower in all cases (64). 
Summarizing, through this approach, the 
chromenopyrazole scaffold has been optimized following a 
dual target anticancer strategy focused on triple-negative 
breast cancer. Cannabinoid quinone 10 was discovered as 
a selective CB2R agonist with potent antiproliferative 
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effects in vitro and in vivo. Its ability to selectively 
decrease viability in cancer versus normal cells, along with 
its striking antitumor capacity, open novel therapeutic 
avenues for the exploitation of the chromenopyrazole 
moiety in cancer physiopathology. In view of these results, 
chromenopyrazoledione 10 can be considered a new 
anticancer drug candidate offering hope for the treatment 
of TNBC.   
4.2. Chromenopyrazolediones for Prostate cancer (PC)  
Prostate cancer (PC) is the second most common 
cancer worldwide for Western men. The rates are  
increasing in recent years since life expectancy is longer 
(80). Even though most prostate cancers grow slowly, 
aggressive cases are also diagnosed. These oncogenic cells 
may metastasize to other parts of the body such as bones 
and lymph nodes (81). Therefore, there are extensive 
ongoing efforts to develop new therapeutic strategies to 
treat prostate cancer (82).  
The basis of medical treatment for advanced prostate 
cancer is androgen deprivation therapy (ADT), intended to 
lower testosterone levels. However, the reduction of 
clinical symptoms and tumor growth is accompanied by 
systemic consequences of testosterone deficiency such as 
osteoporosis, gynecomastia, anemia and insulin resistance 
among others (83,84). Androgen deprivation is associated 
with a gradual transition of prostate cancer cells through a 
spectrum of androgen dependence, androgen sensitivity, 
and ultimately androgen independence. Too often the 
appearance of hormone refractory cancer cells eventually 
leads to the recurrence of cancer which turns to a 
hormone-independent state. This type of prostate cancer 
has a more aggressive phenotype and is unresponsive to 
further hormonal therapy whereby prognosis is very poor. 
Therefore, to find a treatment which could reduce or block 
both types of prostate cancer would be a very good 
challenge to move forward. 
The ECS is also deregulated on the course of this 
pathology. The expression of cannabinoid receptors has 
been studied in prostate cancer tissue. It was demonstrated 
that CB1R expression is upregulated in these neoplasms 
(85). Indeed, high CB1R immunoreactivity score in 
prostate cancer tissue is associated with prostate cancer 
severity and outcome (86). Moreover, expression of 
FAAH (87) and GPR55 (88) is demonstrated in some 
prostate carcinoma cell lines. In line with these 
observations, different endocannabinoids or cannabis-like 
compounds were evaluated exhibiting their ability to 
inhibit prostate cancer cell proliferation and produce 
apoptosis through cannabinoid receptor mechanisms (89). 
The dysregulation of this system correlates with prostate 
cancer grade and progression. Therefore, modulation of 
the ECS may offer novel therapeutic avenues for prostate 
cancer as well (90,91).      
Because of the aforementioned expression patterns in 
prostate cancer, CB1R agonists should provide a new 
therapeutic approach for this type of cancer. Therefore, 
among the series of chromenopyrazolediones previously 
described (figure 8), the para-quinone derivatives, which 
bind to CB1R, were selected for their evaluation in prostate 
cancer-derived cell lines (63). 
Cell viability assays in androgen-dependent (LNCaP) 
and androgen-refractory (PC-3) prostate cancer cell lines 
revealed that these cannabinoid-quinones exhibit 
antiproliferative effects with IC50s in the micromolar 
range. Compound 11 (figure 10), which is the most potent 
among the derivatives tested, displayed an IC50 of 15 µM 
in both  LNCaP and PC-3 prostate cancer cells.  
 
Figure 10. Cannabinoid receptor affinity and half-maximum inhibitory concentrations (IC50) in LNCaP and PC3 cancer cell 
lines of para-chromenopyrazoledione 11.  
Further analysis of chromenopyrazoledione 11 
indicated that it induces cell death through apoptosis, 
being more efficient in the androgen-sensitive LNCaP cell 
line. At a molecular mechanistic level, the cytotoxicity of 
11 was shown to be mediated through CB1R, oxidative 
stress and modulation of the nuclear receptors PPARγ 
(peroxisome proliferator-activated receptors) receptors 
(63). 
In vivo studies of para-quinone 11 confirmed the 
results obtained in vitro. Treatment with 11 at a dose of 2 
mg/kg totally inhibited the growth of androgen-dependent 
prostate tumor xenografts in mice.  
The results obtained for para-chromenopyrazoledione 
11 validated the antiproliferative capacity of 
chromenopyrazole-derived cannabinoid quinones, and 
therefore, the cannabinoid/ROS antitumor proof-of-
concept. 
4.2a Porphyrin conjugate strategy 
In the field of cancer therapy, strategies have been 
explored during these last years in which porphyrins are 
conjugated to molecules showing preferential 
accumulation for tumor tissues or having affinity for 
receptors expressed in tumors (92).  
Porphyrin derivatives constitute the central element of 
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an effective and minimally invasive cancer therapy called 
photodynamic therapy (PDT) (93,94). PDT uses a 
photosensitizing drug, generally a porphyrin derivative, in 
combination with visible light irradiation. In presence of 
the oxygen accumulated in tumors, the photoactive 
sensitizer triggers a series of photochemical processes that 
lead to direct cancer cell death and tumor microvascular 
damage (95,96). PDT is clinically used for the treatment of 
various types of malignant disorders such as bladder, lung 
or esophageal cancer (97). A particular interest of the use 
of these photosensitizers is their preferential accumulation 
by malignant cells due to the presence of high amount of 
collagen and lipids.  
Strategies targeting photosensitizers covalently 
attached to molecules have been reported lately with 
different therapeutic approaches. The photosensitizer can 
be combined with a carrier showing affinity for neoplasia 
or to receptors expressed on specific tumors such as 
monoclonal antibodies, antibody fragments, peptides, 
proteins such as transferrin, epidermal growth factor and 
insulin, low-density lipoproteins, various carbohydrates, 
somatostatin, folic acid among others (98). Another 
strategy will be the conjugation of a therapeutic agent to a 
photosensitizer in view to obtain dual antitumor activity 
and/or to use the photosensitizer as carrier due to their 
ability to preferentially accumulate in cancer tissues (99). 
This strategy has been reported with conjugates such as 
temoporfin/ibuprofen as a non-steroidal anti-inflammatory 
drug (100), tetraphenylporphyrin/trilobolide as a cytotoxic 
agent (101), porphyrazine/doxorubicin (102).  
Two studies on porphyrin/cannabinoid conjugates have 
been reported so far (103,104). The first conjugate 
involved a phthalocyanine named IR700DX-mbc94 with 
the CB2R antagonist SR144528 (103). Phototherapy 
treatment using this complex greatly inhibited the growth 
of expressed CB2R tumors but not tumors that were not 
expressing CB2R. Considering that the CB2R antagonist 
does not have antitumor properties, the strategy used its 
affinity for receptors expressed in tumors to increase the 
accumulation of photosensitizer in the tumor. 
Photosensitizer/chromenopyrazoledione conjugates 
have been proposed recently (figure 11) in which meso-
tetraphenylporphyrin (TPP) was elected as photosensitizer 
and chromenopyrazoledione as antitumor agent (104). 
 
Figure 11. Photosensitizer/chromenopyrazoledione conjugate 14, and the chromenopyrazole 13 and the TPP derivative 12 
involved in its synthesis.  
The synthesis of the porphyrin-chromenopyrazodione 
conjugate 14 was achieved from the porphyrin 12 and the 
chromenopyrazole 13. TPP was regioselectively para-
mononitrated with sodium nitrate to 5-(p-nitrophenyl)-
10,15,20-triphenylporphyrin that was then reduced with tin 
(II) chloride, and finally converted under diglycolic 
anhydride treatment to the carboxylic porphyrin 12. The 
NH-chromenopyrazoledione was first acylated using 
bromoacetyl bromide, and then was allowed to react with 
the carboxylic porphyrin 12 affording the conjugate 14. A 
complete conformational analysis of this 
chromenopyrazole conjugate performed using ab initio 
calculations indicated that the global minimum energy 
conformer adopts an expanded spatial conformation 
whereas folded conformers, where the chromenopyrazole 
and the porphyrin core lay paralleled, exert higher relative 
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energy values. Photophysical properties of the 
chromenopyrazole conjugate 14 showed stronger 
absorption intensity for both Soret (420 nm) and Q-bands 
than the free TPP (500-700 nm). These data are suitable 
for a photosensitizer considering that an ideal 
photosensitizer should have high absorption with 
wavelengths between 600 and 800 nm, no shorter than 600 
nm for tissue penetration and no longer than 800 nm to 
provide enough energy to excite oxygen to its singlet state. 
In what refers to the cannabinoid properties of this 
porphyrin/chromenopyrazole conjugate, it has been 
described to bind weakly but selectively to CB2R.  
In summary, a porphyrin-chromenopyrazole conjugate 
has been designed and synthesized even though the 
syntheses of porphyrin derivatives are known to be 
tedious. The reported photophysical and pharmacological 
properties are suitable for a potential activity as antitumor 
agent.  
5. CHROMENOPYRAZOLES AS GPR55 
MODULATORS  
The orphan G protein-coupled receptor GPR55 (105) 
has been proposed as one of the missing cannabinoid 
receptor types even though it shares low identity with 
CB1R and CB2R (106). GPR55 has been related to the 
endocannabinoid system since CB1R and CB2R ligands 
from diverse origins, endogenous, natural, and synthetic, 
can modulate this receptor. Over these last years, its 
complex cellular signaling pathways and biological 
functions have been the focus of numerous studies (107) 
that identified GPR55 as a promising target for the 
treatment of various pathologies such as inflammation, 
neuropathic pain, bone physiology, diabetes and cancer. 
However, GPR55 validation as a therapeutic target is far 
from being confirmed due to the complexity of GPR55 
downstream signaling and the lack of potent and selective 
GPR55 agonists and antagonists. Effectively, GPR55 
couples to different G-proteins, Gα13, Gαq/11, Gαq /Gα12 or 
Gα12/13 depending on the cell type and GPR55 modulator. 
For instance, stimulation of the Gαq subunit involves the 
phospholipase C with intracellular calcium release with 
possible activation of the MAPK/ERK signaling, whereas 
the Gα12/13 subunit preferably influences the RhoA/ROCK 
signaling pathway. 
L-α-lysophosphatidylinositol (LPI) has been suggested 
to be a GPR55 endogenous ligand (108). GPR55 
modulators from different origins have been reported in 
the literature. A structural update of these GPR55 ligands 
have been recently described in a review (107). GPR55 
ligands include endogenous molecules such as 2-
arachidonoyl-L-α-lysophosphatidylinositol (2-AGPI), N-
arachidonyl glycine (NAGly) (109), and anandamide 
(AEA). The regulation of GPR55 activity by a range of 
phytocannabinoids and synthetic derivatives has been 
described but in some cases it is still controversial (107). 
For instance, Δ9-THC was found to be effective activating 
GPR55 in [35S]GTPγS binding, RhoA assays and 
intracellular calcium mobilization in transiently transfected 
hGPR55-HEK293 cells, whereas it was unable to stimulate 
ERK1/2 phosphorylation nor β-arrestin recruitment. 
Cannabidiol, reported as GPR55 antagonist in [35S]GTPγS 
binding and Rho activation assays, resulted to be inactive 
in Ca2+ mobilization and β-arrestin recruitment 
experiments.  
Among the large number of synthetic cannabinoids 
reported so far, some of them showed to have relevant 
activity at GPR55. Curiously, despite their structural 
diversity, in each family it has been possible to find 
GPR55 modulators (107). The CB1R/CB2 R agonist CP-
55,940, a cyclohexylphenoxy derivative, displayed GPR55 
agonism in [35S]GTPγS evaluation and GPR55 antagonist 
in β-arrestin, ERK phosphorylation and calcium 
mobilization assays. Several diarylpyrazoles such as the 
CB1R antagonist rimonabant, or aminoalkylindoles 
exemplified by WIN55,212-2 interact with GPR55. 
Coumarin and magnolol cannabinoids have also been 
proposed as GPR55 scaffold.   
Few non-CB1R/CB2R-related GPR55 ligands have 
been reported so far (107). High throughput screening of a 
library of compounds from the Sandford-Burnham 
screening center of the Molecular Libraries Probe 
Production Centers Network (MLPCN) allowed the 
identification of different GPR55 scaffolds (110) 
exemplified by triazoloquinoline CID1172084, 
thienopyrimidine CID1434953, and pyrrolopyrazolone 
CID16020046 (figure 12). Data resulting from this 
screening realized with β-arrestin assays in U2OS cells 
permanently expressing HA-GPR55E and βarr2-GFP, 
were confirmed by other biochemical tests from 
independent studies.    
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Figure 12. Some GPR55 ligands identified from a high throughput screening of a library of compounds from MLPCN.  
Following the identification of the CID series as 
GPR55 modulators, N-(4-sulfamoylphenyl)thiourea-based 
GPR55 ligands have been described (111). Interestingly, 
the chromenopyrazole scaffold has also been developed as 
new GPR55 ligands (112). The design of these new 
molecules considered structural features of the GPR55 
activity modulators described in figure 12. Thus, two 
series of chromenopyrazoles (figure 13) were synthesized 
from the 7-methoxy-NH-chromenopyrazole parent that 
was alkylated by the suitable phenylpiperazine in the first 
series, and that was alkylated by 1,3-dibromoethane then 
by the corresponding acylpiperazine in the second series. 
Preparation of the first series has been described with low 
yield due a tedious separation of both N-substituted 
isomers, whereas in the second series, the N-substituted 
isomers were separated at the stage of the N-bromoethyl 
substituted derivative.  
 
 
Figure 13. Two series of chromenopyrazoles as GPR55 ligands. 
The novelty of the reported GPR55 chromenopyrazoles 
comes not only from new structures but also from the 
assay employed for the GPR55 evaluation. So far, the 
potential GPR55 compounds have been explored through 
different functional assays showing in some cases 
discrepancies in the resulting outcomes. These assays 
include β–arrestin recruitment, GTPγS binding, analysis of 
intracellular calcium levels, phosphorylation of ERK1/2, 
and the activation of the small GTPase proteins Rac1, 
RhoA and Cdc42. To overcome the complex signaling 
pathways related to GPR55 activation and the lack of 
GPR55 radioligand, the pharmacological evaluation of the 
chromenopyrazoles was accomplished in a cell-
impedance-based assay. These label-free xCELLigence 
experiments detect cellular morphological changes 
triggered by ligand-dependent GPCR activation and 
coupling to downstream signaling pathways thus providing 
an integrative cellular response. The real-time cellular 
impedance response was monitored in a HEK293 cells 
stably expressing recombinant human GPR55 (hGPR55-
HEK293). Most chromenopyrazoles of series II exhibited 
agonistic GPR55 profile whereas only one compound was 
active in series I. Compared to LPI, active compounds 
have been reported to display partial agonism in hGPR55-
HEK293 cells with good potency showing EC50 values in 
the nanomolar range. One of these potent GPR55 partial 
agonists was selective versus classical CB1R and CB2R. 
The capacity of the chromenopyrazoles to antagonize LPI-
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mediated GPR55 stimulation was also assessed and 
reported. Upon antagonist treatment, three of the 
chromenopyrazoles of series II inhibited LPI effect (1 
µM), being one of them fully selective versus CB1R and 
CB2R. These studies allowed a tuning of compound 
properties that was achieved by small modifications of the 
substitution pattern.  
Additional xCELLigence experiments performed in 
HEK293 cells with active chromenopyrazoles from both 
series allowed to confirm that the cellular responses 
observed in hGPR55-HEK293 cells were mediated 
through GPR55.   
Administration, distribution, and metabolism (ADME) 
properties of the active chromenopyrazoles were predicted 
in silico using a set of 34 physicochemical descriptors 
computed by QikProp. According to this first approach, 
the predicted parameters suggest pharmacokinetic 
improvements compared to LPI that is very insoluble in 
water, air and light sensitive.  
In summary, among the new proposed GPR55 
scaffolds, chromenopyrazole was proposed to constitute a 
versatile scaffold for obtaining potent GPR55 modulators. 
Moreover, evaluation of these chromanopyrazoles at 
GPR55 was described in a cell-impedance-based assay 
integrating complex signaling pathways involved in 
GPR55 activation.  
6. NOVEL CANNABIDIOL DERIVATIVES 
Cannabidiol (CBD) (113) and ∆9-THC are the two 
major phytocannabinoids isolated from Cannabis Sativa. 
CBD and Δ9-THC are biosynthesized through the same 
metabolic pathway from cannabigerolic acid at the 
exception of the last step catalyzed by different enzymes, 
CBDA and THCA synthase respectively. Whereas there is 
a clear structural relationship between both structures, their 
pharmacology differs considerably. For instance, CBD 
does not induce the psychotropic effects associated to ∆9-
THC. Moreover, the complex pharmacology of CBD has 
not been fully elucidated yet. CBD shows only low affinity 
for the cannabinoid receptors CB1R and CB2R, but it 
modulates indirectly the endocannabinoid system through 
fatty acid-binding proteins (FABPs), transient receptor 
potential vanilloid type 1 (TRPV1), 5-hydroxytryptamine 
subtype 1A receptor (5-HT1A), peroxisome proliferator-
activated receptor γ (PPAR-γ), and the A1A adenosine 
receptor (114).  
The therapeutic potential of CBD for 
neurodegenerative diseases, inflammation-related diseases, 
epilepsy, anxiety disorders, and schizophrenia is 
highlighted by numerous preclinical studies (115). Clinical 
trials are already on going for treatment-resistant seizure 
disorders such as Lennox-Gastaut and Dravet syndromes 
and for the treatment of inflammatory bowel diseases 
among others (116). 
Despite the therapeutic interest of CBD, only few CBD 
derivatives have been reported (117). The structural 
modifications of CBD have been realized on the pentyl 
chain introducing heteroatoms or modifying the length of 
the alkyl chain, on the substituents of the cyclohexene, and 
on the cyclohexene itself using bioisosterism with 
cyclopentane or cyclohexane for instance. Replacement of 
the cyclohexene by a nitrogenated-heterocycle has been 
reported in 1983 with the synthesis of 5-pentyl-2-
(pyrrolidin-2-yl)benzene-1,3-diol (118), and more recently 
with the preparation of 5-alkyl-2-(1H-pyrazol-5-
yl)benzene-1,3-diols which are related to the 
chromenopyrazole scaffold (figure 14) (117).  
 
Figure 14. CBD derivatives based on chromenopyrazole 
scaffold.  
Two synthetic route have been reported for the 
synthesis of these 5-alkyl-2-(1H-pyrazol-5-yl)benzene-1,3-
diols illustrated in scheme 2. A Friedel-Crafts acylation of 
the appropriate 3,5-dimethoxyresorcinol followed by α–
formylation and reaction with hydrazine constitutes the 
first synthetic route (scheme 2: Route A). In the second 
synthetic route, 5-dimethylheptyl-2-(1H-pyrazol-5-
yl)benzene-1,3-diol 20 is prepared by reacting hydrazine 
with a chromone previously synthesized from the 
resorcinol olivetol by a succession of acylation and 
hydrolysis to 5-pentyl-2-(1H-pyrazol-5-yl)benzene-1,3-
diol 23 (scheme 2: Route B). These two synthetic 
approaches led to new CBD derivatives which 
pharmacological evaluation has not been reported so far.  
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Scheme 2. Synthesis of 5-alkyl-2-(1H-pyrazol-5-yl)benzene-1,3-diols. Reagents and solvents: Route A: (i) AlCl3, acyl 
chloride, CH2Cl2; (ii) NaH, ethyl formate, MW; (iii) Hydrazine, ethanol; (iv) NaH, 3- bromo-2-methylpropene; (v) Br3B, 
CH2Cl2. Route B: i) AlCl3, acyl chloride, CH2Cl2; ii) Perchloric acid, triethyl orthoformate ; iii) Hydrazine, ethanol. 
 
This work shows that the chromenopyrazole 
experience inspired the design of 5-alkyl-2-(1H-pyrazol-
5-yl)benzene-1,3-diols. So far, two synthetic routes have 
been proposed. With these compounds, the possibility of 
overcoming the psychotropic side effects related to ∆9-
THC still need to be confirmed before pharmacological 
prospection. 
7. SUMMARY AND FUTURE PERSPECTIVES 
The potential of cannabinoid receptor ligands has 
been preclinically explored in the treatment of diverse 
symptoms and diseases such as pain, inflammation, 
metabolic syndromes, cancer, hypertension, bone-related 
disorders or neurodegenerative processes. However, just 
a few of these diseases can be treated with cannabinoid-
based medicines nowadays. Marinol® (dronabinol, 
synthetic Δ9-THC) and Cesamet® (nabilone, a THC 
synthetic analogue) can be prescribed in several countries 
as antiemetic drugs for chemotherapy-induced nausea 
and vomiting (35,36), and for anorexia (119) treatment in 
patients with AIDS. Sativex® (nabiximols, a combination 
of Δ9-THC and CBD, 1:1 ratio) is used for the 
symptomatic relief of neuropathic pain in adults suffering 
multiple sclerosis, and as an adjunctive analgesic 
treatment for adult cancer patients. Rimonabant 
(SR141716A), a CB1R antagonist/inverse agonist, was 
commercialized in Europe in 2006 as Acomplia® for the 
management of obesity (13). Unfortunately, the 
beneficial effects were accompanied by a significantly 
increase of depression, anxiety, headache, and suicidal 
thoughts which forced its withdrawal from the market 
few years later.  
Even though CB1R/CB2R agonists are currently in the 
forefront of clinical research (120) for different 
applications such as epilepsy (Epidiolex®), cancer and 
neuroprotection, there is an increasing interest in 
exploiting novel pharmacological strategies (121). For 
instance, CB2R selective agonists or peripherally 
restricted CB1R/CB2R agonists may exhibit therapeutic 
potential for treating various pathologies while avoiding 
the adverse psychotropic effects related to the modulation 
of CB1R in the brain (122). In addition, CB1R and/or 
CB2R antagonists or inverse agonist as well as allosteric 
cannabinoid ligands which are coming on the scene, may 
be useful in the treatment of certain diseases (121,123). 
Nonetheless, more preclinical and specially clinical 
research needs to be done in this field.  
In this context, the chromenopyrazole scaffold 
emerges as a privileged structure in drug discovery 
targeting the endocannabinoid system. Several papers 
have been published describing the synthesis, the 
pharmacological and biological properties of 
chromenopyrazoles and derivatives. The first 
chromenopyrazoles, described in 1985, did not show 
significant activity in a neuroleptic evaluation. The 
discovery of the endocannabinoid system and specially 
the cannabinoid receptors, allowed exploring this 
scaffold as cannabinoid ligand. Structural modifications 
on the chromenopyrazole core allowed the development 
of cannabinoid drugs with a broad therapeutic prospect. 
Strategies pursued so far in this field have been 
summarized in figure 15. Phenolic chromenopyrazole 
derivatives were claimed in 2012 as non-psychoactive 
and selective CB1R agonists with peripheral 
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antinociceptive properties (18). Structural modifications 
of the chromenopyrazole core allowed fine-tuning of 
cannabinoid receptor affinity and activity. Structural 
features required for CB1R/CB2R affinity and selectivity 
were determined using molecular modeling. These 
studies led to the identification of a potent and selective 
CB2R agonist with confirmed neuroprotective properties 
in murine models of neurodegenerative disorders (25,26).  
Further exploration of this scaffold allowed the 
design of multifunctional chromenopyrazoles. This 
strategy involved targeting different anticancer modes of 
action in a single molecule. The antitumor properties of 
cannabinoids and the redox properties characterizing 
quinones were fused in chromenopyrazolediones (figura 
15).  The antiproliferative activity of these new 
compounds was successfully explored in vitro and in vivo 
in breast and prostate cancer models (63,64). 
The chromenopyrazole scaffold was also exploited 
for the modulation of the putative cannabinoid receptor 
GPR55. Two series of compounds have been reported 
(112). Their ability to activate GPR55 was measured 
through an innovative label-free cell impedance assay 
allowing the discovery of novel chromenopyrazole 
GPR55 partial agonists and antagonists.  
The last approach pursued in the exploration of this 
scaffold is the development of CBD-related 
chromenopyrazoles (117). Even though their therapeutic 
potential has not been reported yet, the nature of its 
resorcinol core may provide interesting antioxidant 
properties. Possible activity at cannabinoid related targets 
such as GPR3, GPR6, GPR12, GPR55 or GPR18 should 
be considered when evaluating this compound since CBD 
modulates all of them with moderate potencies (124–
127). 
 
Figure 15. Summary of the chromenopyrazole derivatives reported so far and their pharmacological profile. 
New chromenopyrazoles could be synthesized and 
screened against other relevant biological targets of the 
endocannabinoid system or related targets. Apart from the 
potential of chromenopyrazoles as therapeutic agents, they 
also should be considered tools to validate new biological 
targets. 
Activation of the CB1R and CB2R has been shown to 
induce different cellular signaling cascades through 
coupling to different effector proteins: G-protein (Gαi/o) 
and β-arrestins (1/2) (128–130). The search for a ligand 
that can induce specific receptor activation profiles 
resulting in specific subsets of signaling pathways (biased 
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signaling) has recently received a special attention in the 
field of GPCRs research (129,131–133). This is due to the 
possibility of attaining different therapeutic effects and/or 
avoiding untoward effects while targeting the same 
receptor protein (134). In this direction, a deeper 
functional analysis of the chromepyrazoles reviewed 
herein should also be pursued by evaluation of diverse 
signaling pathways using different readouts. Functionally 
profiling these compounds may lead to fine-tuning the 
chromenopyrazole chemotype in order to identify novel 
biased agonists of the cannabinoid receptors.  
An important step to move forward in the drug 
discovery process is to evaluate the pharmacokinetic 
profile of the candidates. In silico ADME predictions 
suggested that chromenopyrazoles have a favorable 
druggability profile, however, in vitro and in vivo data of 
the most promising lead compounds is needed to confirm 
the pharmacokinetic properties of these novel derivatives.  
Albeit more research is clearly needed to continue 
towards more preclinical evaluation, the efforts done for 
the development of modulators of the ECS based on the 
chromenopyrazole heterocycle open new avenues in the 
cannabinoid field. Novel pharmacological tools to study 
orphan receptors, as well as potential candidates for the 
treatment of diverse pathologies can be optimized using 
the outstanding starting point provided by the versatile 
chromenopyrazole chemotype. 
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